Opportunities for Licensing ***


Opportunities for Licensing

Bio Balance offers a unique opportunity to partner into a ground-breaking  process to create and develop better drugs. Bio Balance is committed to offering the best value to pharmaceutical or biotech partners for new drug development. Bio Balance currently has an improved dobutamine for heart failure and isoproterenol for emergency management (DOB+ and ISO+).  Bio Balance is seeking a collaborative partner to take these potential products to the next level of development. Other areas of potential development include enhancing drugs that treat Parkinson's disease, memory loss, asthma, heart failure, or other diseases that require new or improved drugs.

To contact Bio Balance about Licensing opportunities -contact:

Dr. Richard Lanzara
Bio Balance Inc.
30 West 86th St.
New York, N.Y. 10024-3600

Tel: (917) 623-2074
Fax: (212) 769-3877

Therapeutic Compositions to Prevent Desensitization

Specific compositions from the patent USP 6,593,094 titled "Compositions to enhance the efficacy and safety of bio-pharmaceutical drugs" are available for licensing to either biotechnology or pharmaceutical firms or for collaborative development - see this link.


Our technology is at the forefront of cutting edge science, but just beginning. Although agonist/antagonist combinations have been used before, we have perfected the science so that we have the best method of determining the optimal agonist/antagonist ratio. This means better and safer drugs. Almost one third of all drugs could be improved by this technology.  This technology is available for licensing or collaborative development (this technology is transferred to Enhanced Pharmaceuticals see this link for contact information).

One of the perils of drug development is the occurrence of desensitization, which is also called tolerance, fade, tachyphylaxis or down-regulation.  Many in the industry believe that by selecting the proper dosage regime drug-receptor desensitization can be minimized or prevented.  Rightly or wrongly, they create a tightrope that patients and doctors must walk when utilizing these types of medications.  This may affect anywhere from 30 to 50 percent of all pharmaceuticals and be a fertile area for drug development and improvement in the future.  Given some of the disturbing reports that shown upwards of 90,000 cases per year of reported medical errors, the production of safer drugs should be a top priority in the pharmaceutical field.  Yet why haven't the major companies done more to produce safer drugs?  A partial explanation would be that it is much more expensive to ensure safer drugs, but an alternative explanation may be that they lack the technology to understand and correct the problem. Certainly, the major companies would want the safest product on the market.  This would not only make sense from a medical standpoint, but from a marketing one as well. Safer drugs require that all of the variables of drug development be evaluated and adjusted for the greatest number of people using these medications.  Surprisingly, the safest drugs may come from using agonist/antagonist combinations in ways to prevent, diminish or control drug-receptor desensitization.  This would be analogous to creating designer partial agonists in ways that have been previously overlooked, but would offer a new technology for enhancing the safety and efficacy of many pharmaceuticals.

The following list suggests some of the advantages of agonist/antagonist compositions:

1.        less expensive to develop. 

2.        better control of the therapeutic response.

3.        would enhance existing pharmaceuticals by enlarging their therapeutic window.

4.        extend patent protection of large-cap drugs.

5.        these compositions can be licensed for applications in specific fields (eg. cardiovascular, pulmonary, renal, etc.).

6.        potentially quick acceptance by physicians as a technically superior design of previously accepted drugs.

7.        much of the toxicity, carcinogenicity and teratogenic testing has been done because these are already FDA approved drugs.

8.        trials could be started rapidly.

9.        molecules do not need to be designed from scratch.

10. could salvage previously discarded molecules due to excessive desensitization or fade at the receptor.

11. could be used to determine the optimal mixtures of chiral molecules.

Web Page: